{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:34:33Z","timestamp":1759667673656,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13287-018-0901-6","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T08:56:11Z","timestamp":1527670571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger\u2019s disease)"],"prefix":"10.1186","volume":"9","author":[{"given":"Jorge D.","family":"Martin-Rufino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco S.","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba M.","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Villaron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Fernandez-Samos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7076-7739","authenticated-orcid":false,"given":"Fermin","family":"Sanchez-Guijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"issue":"5","key":"901_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1024\/0301-1526\/a000371","volume":"43","author":"PF Klein-Weigel","year":"2014","unstructured":"Klein-Weigel PF, Richter JG. Thromboangiitis obliterans (Buerger\u2019s disease). Vasa. 2014;43(5):337\u201346.","journal-title":"Vasa"},{"key":"901_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.amsu.2016.03.028","volume":"7","author":"IJ Rivera-Chavarr\u00eda","year":"2016","unstructured":"Rivera-Chavarr\u00eda IJ, Brenes-Guti\u00e9rrez JD. Thromboangiitis obliterans (Buerger\u2019s disease). Ann Med Surg. 2016;7:79\u201382.","journal-title":"Ann Med Surg"},{"key":"901_CR3","doi-asserted-by":"crossref","unstructured":"Sun XL, Law BY, de Seabra Rodrigues Dias IR, Mok SWF, He YZ, Wong VK. Pathogenesis of thromboangiitis obliterans: gene polymorphism and immunoregulation of human vascular endothelial cells. Atherosclerosis. 2017;265:258\u201365.","DOI":"10.1016\/j.atherosclerosis.2017.08.009"},{"issue":"1","key":"901_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1365-2249.2012.04624.x","volume":"170","author":"R Dellalibera-Joviliano","year":"2012","unstructured":"Dellalibera-Joviliano R, Joviliano EE, Silva JS, Evora PRB. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin Exp Immunol. 2012;170(1):28\u201335.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"901_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/nyas.12048","volume":"1285","author":"SS Ketha","year":"2013","unstructured":"Ketha SS, Cooper LT. The role of autoimmunity in thromboangiitis obliterans (Buerger\u2019s disease). Ann N Y Acad Sci. 2013;1285(1):15\u201325.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"901_CR6","doi-asserted-by":"publisher","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji H-L, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062.","journal-title":"Cell Death Dis"},{"issue":"3","key":"901_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.5966\/sctm.2016-0237","volume":"6","author":"PK Gupta","year":"2017","unstructured":"Gupta PK, Krishna M, Chullikana A, Desai S, Murugesan R, Dutta S, et al. Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger\u2019s disease: phase ii study report suggests clinical efficacy. Stem Cells Transl Med. 2017;6(3):689\u201399.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"901_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3727\/215517916X693069","volume":"9","author":"JC Ra","year":"2017","unstructured":"Ra JC, Jeong EC, Kang SK, Lee SJ, Choi KH. A prospective, nonrandomized, no placebo-controlled, phase I\/II clinical trial assessing the safety and efficacy of intramuscular injection of autologous adipose tissue-derived mesenchymal stem cells in patients with severe Buerger\u2019s disease. Cell Med. 2017;9(3):87\u2013102.","journal-title":"Cell Med"},{"issue":"10","key":"901_CR9","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.117.310599","volume":"120","author":"D Luger","year":"2017","unstructured":"Luger D, Lipinski MJ, Westman PC, Glover DK, Dimastromatteo J, Frias JC, et al. Intravenously-delivered mesenchymal stem cells: systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy. Circ Res. 2017;120(10):1598\u2013613.","journal-title":"Circ Res"},{"issue":"10","key":"901_CR10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.bbmt.2014.06.015","volume":"20","author":"F S\u00e1nchez-Guijo","year":"2014","unstructured":"S\u00e1nchez-Guijo F, Caballero-Vel\u00e1zquez T, L\u00f3pez-Villar O, Redondo A, Parody R, Mart\u00ednez C, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(10):1580\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"901_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jcyt.2013.01.218","volume":"15","author":"J Wang","year":"2013","unstructured":"Wang J, Liao L, Wang S, Tan J. Cell therapy with autologous mesenchymal stem cells\u2014how the disease process impacts clinical considerations. Cytotherapy. 2013;15(8):893\u2013904.","journal-title":"Cytotherapy"},{"issue":"1","key":"901_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jvs.2008.12.073","volume":"50","author":"SPA Nicola\u00ef","year":"2009","unstructured":"Nicola\u00ef SPA, Kruidenier LM, Rouwet EV, Graffius K, Prins MH, Teijink JAW. The walking impairment questionnaire: an effective tool to assess the effect of treatment in patients with intermittent claudication. J Vasc Surg. 2009;50(1):89\u201394.","journal-title":"J Vasc Surg"},{"key":"901_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, De Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337\u201343.","journal-title":"Ann Med"},{"issue":"2","key":"901_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1365-3148.2012.01134.x","volume":"22","author":"S Munti\u00f3n","year":"2012","unstructured":"Munti\u00f3n S, S\u00e1nchez-Guijo FM, Carrancio S, Villar\u00f3n E, L\u00f3pez O, Diez-Campelo M, et al. Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use. Transfus Med. 2012;22(2):122\u20137.","journal-title":"Transfus Med"},{"key":"901_CR15","doi-asserted-by":"crossref","unstructured":"Coutinho T, Rooke TW, Kullo IJ. Arterial dysfunction and functional performance in patients with peripheral artery disease: a review. Vasc Med. 2011;16:203\u201311.","DOI":"10.1177\/1358863X11400935"},{"key":"901_CR16","doi-asserted-by":"crossref","unstructured":"de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells. 2018;36:602\u201315.","DOI":"10.1002\/stem.2779"},{"issue":"4","key":"901_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13577-014-0095-x","volume":"27","author":"B Amorin","year":"2014","unstructured":"Amorin B, Alegretti AP, Valim V, Pezzi A, Laureano AM, da Silva MAL, et al. Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. Hum Cell. 2014;27(4):137\u201350.","journal-title":"Hum Cell"},{"issue":"1","key":"901_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jocit.2014.12.001","volume":"2","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Ren H, Han Z. Mesenchymal stem cells: immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother. 2016;2(1):3\u201320.","journal-title":"J Cell Immunother"},{"key":"901_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3727\/096368915X689622","volume":"25","author":"U Galderisi","year":"2016","unstructured":"Galderisi U, Squillaro T, Peluso G. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25:829\u201348.","journal-title":"Cell Transplant"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-018-0901-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13287-018-0901-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-018-0901-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T19:12:54Z","timestamp":1559157174000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-018-0901-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1186\/s13287-018-0901-6","relation":{},"ISSN":["1757-6512"],"issn-type":[{"type":"electronic","value":"1757-6512"}],"subject":[],"published":{"date-parts":[[2018,5,30]]},"assertion":[{"value":"29 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the procedures reported were in accordance with the ethical standards of the 1975 Helsinki Declaration and its later amendments and were approved by the Ethics Committee of the Hospital Universitario de Salamanca (Spain). Informed consent was obtained from the MSC-treated TAO patient and the MSC donor. Appropriate approval was also obtained from the Spanish Medicines Agency (AEMPS).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient\u2019s written informed consent for publication was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"150"}}